Published • loading... • Updated
Eli Lilly Ups Revenue Forecast as GLP-1 Drugs Fuel Growth
The drugmaker lifted its sales forecast after second-quarter revenue beat estimates, with U.S. revenue up 33% and Mounjaro sales rising 91%.
- Eli Lilly reported second-quarter earnings of $8.38 per share and $22.97 billion in revenue, beating Wall Street expectations and raising its 2026 revenue guidance to between $85 billion and $87 billion.
- Resilient demand for Zepbound and Mounjaro fueled the strong performance, with worldwide Mounjaro revenue rising 91% to $9.94 billion and Zepbound posting $4.93 billion in revenue, up 44% from the year-earlier period.
- International revenue jumped 80% to $8.6 billion, driven by a 113% volume surge, though Mounjaro's inclusion in China's state-run health insurance for Type 2 diabetes contributed to lower realized prices.
- Lilly is executing a historic M&A spending spree, purchasing three vaccine makers and a psychedelics drugmaker, while Foundayo generated $98 million in revenue during its first earnings report.
- Eli Lilly CEO Dave Ricks expects global GLP-1 use to reach 30 million patients by the end of 2026, as both Lilly and Novo Nordisk anticipate benefits from Medicare's obesity drug coverage launched in early July.
Insights by Ground AI
28 Articles
28 Articles
Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo
Sales of Eli Lilly's Zepbound and Mounjaro injectable weight-loss and diabetes drugs soared during the second quarter, easily beating Wall Street estimates and widening the gap with Danish rival Novo Nordisk .
·London, United Kingdom
Read Full Article
GLP-1’s Drove Eli Lilly’s Record-Breaking Q2, but AI Will Be Its Future
The market has spent the past two years treating pharmaceutical stocks like a referendum on GLP-1 drugs. That has been justified. Weight-loss and diabetes therapies have reshaped the industry’s growth outlook and created a handful of blockbuster winners. Yet markets have a habit of looking backward. The companies that generate today’s profits are not always ... GLP-1’s Drove Eli Lilly’s Record-Breaking Q2, but AI Will Be Its Future
·Lakewood, United States
Read Full Article
Coverage Details
Total News Sources28
Leaning Left2Leaning Right6Center10Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
11%
C 56%
R 33%
Factuality
To view factuality data please Upgrade to Premium
